Editorial note: this article summarises published research on BPC-157. Baclabs does not sell BPC-157 or any peptide; we supply bacteriostatic water and reconstitution consumables. Nothing here is medical advice.
BPC-157 is sold as a freeze-dried powder in 5 mg or 10 mg vials, and most practical questions about it (how much water to add, what a syringe unit contains, how long the solution lasts, whether swallowing it does anything) are about handling rather than pharmacology. This guide answers them with worked arithmetic, sets out the dose ranges in the published literature with their sources, and compares the oral and injectable routes on the evidence.
Two caveats throughout: BPC-157 has no published randomised controlled human trial, so the dose figures come from rat studies, a pharmacokinetic paper and small uncontrolled human reports [1][2][3]; and it is not a licensed medicine anywhere and is prohibited in sport [4]. The wider picture is on the regenerative peptides hub.
What is in the vial
BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide, sequence GEPPPGKPADDAGLV, usually supplied as an acetate salt, lyophilised (freeze-dried) with no diluent. Whether the label mass is accurate depends on the certificate of analysis, discussed in the purity and regulation article.
It is called a “stable gastric pentadecapeptide” because, unlike most peptides, it survives in human gastric juice for more than 24 hours [5].
BPC-157 reconstitution guide: the maths for a 5 mg vial
Reconstitution converts a known mass of powder into a solution of known concentration. The formula is:
Concentration (mcg/mL) = peptide mass (mcg) ÷ diluent volume (mL)
5 mg is 5,000 mcg. A U-100 insulin syringe is graduated in units, each of which is 0.01 mL, so 100 units is 1 mL. Multiply the concentration by 0.01 to get micrograms per unit.
| Bacteriostatic water added to 5 mg | Concentration | mcg per unit (0.01 mL) | Units for 200 mcg | Units for 250 mcg | Units for 500 mcg |
|---|---|---|---|---|---|
| 1 mL | 5,000 mcg/mL | 50 mcg | 4 | 5 | 10 |
| 2 mL | 2,500 mcg/mL | 25 mcg | 8 | 10 | 20 |
| 2.5 mL | 2,000 mcg/mL | 20 mcg | 10 | 12.5 | 25 |
| 3 mL | 1,667 mcg/mL | 16.7 mcg | 12 | 15 | 30 |
| 5 mL | 1,000 mcg/mL | 10 mcg | 20 | 25 | 50 |
Worked example: 5 mg + 2 mL = 2,500 mcg/mL. Each unit on a U-100 syringe holds 25 mcg, so 10 units is 250 mcg and 20 units is 500 mcg. The 200/250/500 mcg columns illustrate the arithmetic for amounts commonly discussed online; they are not recommendations. For a 10 mg vial, double every concentration figure.
Technique and stability
Swab the stoppers of both vials, draw the chosen volume of bacteriostatic water, and inject it slowly down the inside wall of the peptide vial rather than onto the powder. Roll or swirl gently; do not shake, because agitation can cause peptides to aggregate, and aggregation is one of the FDA’s stated immunogenicity concerns for this compound [6]. The solution should be clear and colourless.
Multi-dose use is why the diluent matters. A vial that is punctured every day for three weeks needs a preservative in the water; bacteriostatic water contains 0.9% benzyl alcohol for that reason, whereas sterile water for injection has none and is meant for single use. The comparison is in bacteriostatic vs sterile water. Baclabs supplies UK-stocked bacteriostatic water in 30 mL vials; the reconstitution guide covers technique in full.
There are no published stability studies of reconstituted BPC-157 in bacteriostatic water at the concentrations above. General peptide practice is to refrigerate at 2–8 °C after reconstitution, keep it out of light, and use the bacteriostatic water vial for no more than 28 days after first puncture, the window the preservative is validated for; see storage and shelf life. Lyophilised powder is more stable than solution.
Dose ranges reported in the literature
Every figure below has a named source, and none is an instruction.
| Source | Species and route | Dose reported |
|---|---|---|
| Sikirić group rodent studies, reviewed 2021 [1] | Rat; intraperitoneal once daily | 10 µg/kg and 10 ng/kg (also 10 pg/kg) |
| Same [1] | Rat; oral in drinking water | 0.16 µg/mL, about 12 mL per rat per day |
| Same [1] | Rat; topical | 1 µg/g in neutral cream |
| He et al. 2022 pharmacokinetics [2] | Rat and dog; intramuscular and intravenous | 20–500 µg/kg (rat), 6–150 µg/kg (dog); “proposed clinical dose” 200 µg/person/day stated but not tested for efficacy |
| Retrospective knee series 2021 [3] | Human; intra-articular, single injection | 2 mL of 2,000 mcg/mL (4 mg), some with thymosin beta-4 added; no control group |
| Intravenous pilot 2025 [7] | Human; IV infusion, two healthy adults | Up to 20 mg; no adverse effects reported |
Scaled naively, 10 µg/kg in an 80 kg adult is 800 mcg, but rat-to-human scaling by body surface area rather than weight divides that by roughly six, giving a figure in the low hundreds of micrograms. The point is that the daily doses quoted on vendor pages and forums are at best extrapolations from rat data, not tested human doses, and we do not reproduce them. No dose-response study in humans exists, and the FDA’s 2026 briefing document described the human safety information as insufficient to characterise the compound’s safety profile [6]. Rodent studies report no toxicity and no reachable LD1 [1], which says something about acute toxicity and nothing about long-term use.
BPC 157 oral vs injection: what the evidence supports
The oral argument is that BPC-157 is stable in gastric juice and the Sikirić studies report equal effects from drinking water and injection. The counter-argument is that peptides are not absorbed intact across the gut wall, so oral BPC-157 can only act locally. The data:
- Gastric stability is real. BPC-157 survives more than 24 hours in human gastric juice [5]. This is unusual and removes the first barrier to oral activity.
- Rodent studies report oral efficacy for systemic injuries. The 2021 review states that the same dose range and “equipotent routes” (intraperitoneal, intragastric, topical) were effective across tendon, muscle and other models [1]. This is the strongest evidence for the oral route, and it all comes from one group.
- Pharmacokinetics argue for poor systemic exposure. The 2022 rat and dog study found an elimination half-life under 30 minutes, intramuscular bioavailability of 14–19% in rats and 45–51% in dogs, and rapid hydrolysis to amino acids [2]. Oral bioavailability was not measured, but a peptide with a 15-minute half-life and low intramuscular bioavailability is unlikely to reach meaningful blood levels from the gut.
- Human data exist only for injection. The two-person IV pilot and the intra-articular knee series are parenteral; no human oral study has been published [3][7].
A reasonable reading is that oral BPC-157 is plausible for gastrointestinal targets, which is what Pliva originally developed it for, and unproven for tendon, ligament or muscle. Injection produces measurable systemic exposure in animals but carries the immunogenicity and sterility risks that oral dosing avoids. Neither route has controlled human efficacy data, and subcutaneous versus intramuscular, or local versus distant injection, has never been compared in a published study.
Regulatory reminder
BPC-157 was placed on Category 2 of the FDA’s 503A bulk substances list in September 2023, which bars US pharmacy compounding; a July 2026 advisory committee voted narrowly to reverse that, but the vote is non-binding and nothing has yet changed [8][9]. In the UK, supplying it as a medicine breaches the Human Medicines Regulations 2012, and the MHRA has said “research use” labelling does not alter that where human use is intended [10][11]. It is prohibited at all times under WADA’s S0 category [4]. Combination with TB-500 is covered in the Wolverine stack article.
Frequently asked questions
How much bacteriostatic water do you add to a 5 mg BPC-157 vial?
Any volume the vial can hold works; what changes is the concentration. 1 mL gives 5,000 mcg/mL (50 mcg per insulin unit), 2 mL gives 2,500 mcg/mL (25 mcg per unit), 5 mL gives 1,000 mcg/mL (10 mcg per unit). Two millilitres is the common choice because the arithmetic is simple and draws stay small.
What BPC-157 dose is used in the research?
Rat studies from the Sikirić group used 10 µg/kg or 10 ng/kg daily by injection, or 0.16 µg/mL in drinking water. A 2022 pharmacokinetic paper mentions a proposed clinical dose of 200 µg per day that was never tested for efficacy. The only human reports used a 4 mg intra-articular injection or up to 20 mg intravenously in two people. No human dose-response study exists.
Is oral BPC-157 as effective as injection?
Unknown in humans. BPC-157 is stable in gastric juice and rat studies from one group report equal effects by mouth and by injection. Pharmacokinetic data show a half-life under 30 minutes and modest bioavailability even by intramuscular injection, which argues against meaningful systemic absorption from the gut. Oral use is most plausible for gut targets.
How long does reconstituted BPC-157 last in the fridge?
No published stability study answers this for bacteriostatic water at typical concentrations. Standard peptide practice is refrigeration at 2–8 °C, protection from light, and using the bacteriostatic water within 28 days of first puncture, the period its benzyl alcohol preservative is validated for. Discard any solution that turns cloudy or shows particles.
References
- Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Seiwerth S, Sikiric P et al., Frontiers in Pharmacology, 2021
- Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. He L et al., Frontiers in Pharmacology, 2022
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. 2021 (PMID 34324435)
- BPC-157: Experimental Peptide Creates Risk for Athletes. US Anti-Doping Agency
- Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy. Sikiric P et al., Current Pharmaceutical Design, 2020 (PMID 32329684)
- FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting: BPC-157. US FDA, July 2026
- Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. 2025 (PMID 40131143)
- 503A Bulk Drug Substances Categories Update, September 29 2023. Alliance for Pharmacy Compounding, 2023
- FDA Panel Backs 6 Peptides for Compounding. AJMC, July 2026
- The Human Medicines Regulations 2012, Regulation 46. legislation.gov.uk
- Grey-market peptides: what pharmacists need to know. The Pharmacist, April 2026
Disclaimer: This content is for educational purposes only and does not constitute medical advice. Bacteriostatic water is supplied for reconstitution of substances intended for research and for use as directed by a healthcare professional. Peptides and medicines discussed here may be unlicensed in the UK or prescription-only; consult a qualified clinician before using any medicine. Baclabs does not sell peptides.